Essential Pharma Acquires Yorkdale Pharma from Rosemont; Sells Oral Liquid Portfolio to Rosemont and Buys Two Product Rights from Novartis

Essential Pharma Acquires HALDOL Rights from Janssen Pharmaceutica NV

December 7, 2022

Pharmaceuticals

Gyrus Capital-backed Essential Pharma has acquired global rights to HALDOL (haloperidol) and HALDOL Decanoate from Janssen Pharmaceutica NV. The deal expands Essential Pharma's specialty CNS portfolio and secures continued global supply of this WHO-listed essential antipsychotic marketed in the US and more than 60 countries.

Essential Pharma Acquires Renaissance Pharma Ltd

April 2, 2024

Pharmaceuticals

Essential Pharma has completed the acquisition of all issued share capital of Renaissance Pharma Ltd, gaining the clinical-stage immunotherapy Hu14.18K322A (Hu14.18) for treatment of high‑risk neuroblastoma. The deal adds a development‑stage rare disease oncology asset to Essential Pharma's portfolio; Renaissance's CEO Simon Ball and members of the Renaissance team will continue to work with Essential on further development in partnership with St. Jude Children's Research Hospital.

Essential Pharma Acquires Reminyl Oral Capsules from Janssen Pharmaceutica

April 18, 2024

Pharmaceuticals

Essential Pharma has acquired rights to Reminyl (galantamine hydrobromide) oral capsules from Janssen Pharmaceutica NV (a Johnson & Johnson company). The deal transfers rights in the EEA, South Korea, Thailand and other current markets (excluding the UK & Ireland, Japan and Latin America), expanding Essential Pharma’s CNS portfolio and its presence in the Asia‑Pacific region.

Alora Pharmaceuticals Acquires Osmotica's Legacy U.S. Business

August 30, 2021

Pharmaceuticals

Alora Pharmaceuticals, LLC closed the acquisition of Osmotica Pharmaceuticals plc's legacy U.S. business (including Osmotica Pharmaceutical US LLC, Vertical Pharmaceuticals, LLC and Trigen Laboratories, LLC) and the Marietta, Georgia manufacturing facility on August 27, 2021. Osmotica received approximately $111 million in proceeds, which it said would be used to retire a substantial portion of outstanding debt and to focus the company on its ophthalmic product UPNEEQ.

Tilley Company (SK Capital) Acquires Phoenix Aromas & Essential Oils

December 1, 2021

Food & Beverage

Baltimore-based Tilley Company, a portfolio company of SK Capital Partners, has completed a merger with Phoenix Aromas & Essential Oils, creating the combined Tilley‑Phoenix Group. The transaction — an add-on to Tilley's platform — was announced December 2021 and was reported as an exit for Caymus Equity Partners, expanding Tilley's product portfolio, technical/regulatory capabilities and global distribution in flavor & fragrance and other regulated markets.

AmerisourceBergen Acquires PharmaLex from AUCTUS in €1.28bn Transaction

December 31, 2022

Healthcare Services

AmerisourceBergen Corporation acquired a majority stake in PharmaLex from funds advised by AUCTUS Capital Partners AG in a transaction that closed at year-end 2022 for approximately EUR 1.28 billion. PharmaLex, a Germany-headquartered provider of regulatory, clinical development and pharmacovigilance services to the life sciences industry, was grown under AUCTUS through a buy-and-build program of 38 add-ons and will expand AmerisourceBergen's global pharmaceutical solutions.